Athira's Alzheimer's Drug Passes Futility Analysis; Data Targeted For 2024
Executive Summary
An unblinded interim efficacy analysis by a DMC recommended a Phase II/III study testing fosgonimeton in Alzheimer's patients should continue.
You may also be interested in...
A Banner Moment For Alzheimer's Positions Eisai/Biogen At The Head Of The Pack
Eisai and Biogen, who have an accelerated approval decision pending in the US, said they will seek traditional approvals for lecanemab by Q1 2023 based on positive results from the Phase III Clarity AD trial.
Athira Says Phase II Alzheimer’s Miss Will Inform Ongoing Phase III Study
Athira hoped a small Phase II study would show a benefit on working memory processing speed, but it missed its primary and all secondary endpoints, reducing confidence in the Phase III program.
Astellas Plots US Portfolio Expansion
US president Mark Reisenauer talked to Scrip about the company's next growth drivers, including fezolinetant for vasomotor symptoms and zolbetuximab for gastric cancer.